drugset / Trial / NCT07280299
Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the efficacy, the safety, and the effect on biomarkers of 2 dose levels of oral GT-02287 over placebo after 48 weeks of treatment in treated and untreated participants with early PD.
Timeline
- Start
- 2026-05-30
- Primary completion
- 2028-06-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | GT-02287 | Unknown | 400 mg | Oral |
| Comparator | GT-02287 | Unknown | 600 mg | Oral |
| Comparator | GT-02287 | Unknown | 800 mg | Oral |
| Comparator | GT-02287 | Unknown | 1000 mg | Oral |